Analysis of the Global Oncology Drug Delivery Market
Analysis contained in this research service is based on the following:
Information collected through discussions with market participants and from secondary sources, including pharmaceutical companies and medical devices companies involved in drug delivery systems as well as other Websites and credible sources.
Public announcements and plans by key market leaders, suppliers, new entrants, and others.
Frost & Sullivan’s published research and market and technology expertise. All market figures and shares listed in the research are Frost & Sullivan's assessment based on its research. For Market Engineering research, Frost & Sullivan utilises tried and tested marketing techniques to provide structure to the research and an easy format to compare results across different countries and markets. This project was carried out using primary (telephone) and secondary (published and online material) research as the principle methods of data gathering. The focus of the interviews for this project was primarily the respondent types outlined below.
Key regulatory bodies
Frost & Sullivan published research services
Decision support databases
Country industry forecasts
Annual reports published by companies
About this report
The global oncology drug delivery market (or oncolytics market) was worth $91.00 billion in 2013 and has been growing at an annual rate of 5.0%. The market, which includes drug delivery systems for cancer therapy and cancer pain, is expected to generate $100.96 billion in 2015. The oral drug delivery systems segment accounted for an estimated 25.0% of the total global market in 2013 and will continue to grow stronger in 2015. Currently, the injectable drug delivery system segment leads the cancer drug delivery market; however, nanoparticles (including micro-needles, patches, and orals) are expected to lead the market in the future.
Electronic Access - Site License Fulfilled By Publisher
Electronic Access - Global site License Fulfilled By Publisher